Is there evidence that low vitamin D can contribute to periodic limb movements (PLMs) or restless legs syndrome (RLS)?

Vitamin D Deficiency and RLS/PLMs: Evidence and Clinical Implications

The most recent 2025 AASM clinical practice guideline for RLS and PLMD does not include vitamin D supplementation in its treatment recommendations, despite emerging research evidence suggesting an association between low vitamin D levels and RLS. 1

What the Guidelines Say

The 2025 AASM guideline comprehensively addresses RLS and PLMD treatment but makes no mention of vitamin D as either a contributing factor or therapeutic intervention. The guideline focuses on:

• Strong recommendations for gabapentinoids (gabapentin enacarbil, gabapentin, pregabalin) and IV iron formulations 1
• Iron supplementation (ferrous sulfate) with conditional recommendations based on appropriate iron parameters 1
• No recommendations regarding vitamin D screening or supplementation

Notably, the 2024 Endocrine Society guideline on vitamin D for disease prevention also does not address RLS or PLMs as conditions warranting vitamin D supplementation 2.

What the Research Evidence Shows

Despite guideline silence, recent research demonstrates consistent associations between vitamin D deficiency and RLS:

Most Recent High-Quality Evidence (2025)

Two 2025 studies provide the strongest recent evidence:

1. Post-stroke RLS study 3: Patients with RLS after acute ischemic stroke had significantly lower vitamin D levels (p < 0.001). Vitamin D was an independent predictor (OR = 0.673,95% CI: 0.610-0.743, p < 0.001) with excellent predictive value (AUC 0.915, cutoff 18.15 ng/mL, sensitivity 84.4%, specificity 90.6%). Lower vitamin D correlated with more severe RLS symptoms.

2. Pediatric RLS treatment study 4: In children with RLS and vitamin D deficiency, supplementation significantly improved bedtime resistance, sleep onset delay, sleep anxiety, parasomnias, daytime sleepiness, and total sleep scores compared to pre-treatment. No improvements occurred in RLS patients without vitamin D deficiency who didn't receive supplementation.

Supporting Evidence

• 2023 pregnancy study 5: ROC and CART analyses identified vitamin D cutoff values of 10-12.7 ng/mL associated with RLS. Of women with persistent moderate-to-severe postpartum RLS, 4 of 5 had vitamin D < 10 ng/mL.

• 2024 fortified dairy study 6: In women with severe PMS (PSST > 28), vitamin D fortification significantly increased serum levels and reduced RLS severity (p < 0.05).

• 2023 comprehensive review 7: Concluded that vitamin D deficiency is common enough in RLS patients to suggest checking levels and correcting deficiency as standard of care, despite inconsistent literature.

Clinical Approach: Bridging the Guideline-Research Gap

When to Check Vitamin D in RLS/PLM Patients

Check 25(OH)D levels in:

• All RLS patients, particularly those with:
  • Moderate-to-severe symptoms
  • Inadequate response to first-line therapies (gabapentinoids, iron)
  • Post-stroke RLS
  • Pregnancy-related RLS
  • Pediatric RLS
  • Risk factors for vitamin D deficiency (limited sun exposure, dark skin, malabsorption, obesity)

Treatment Thresholds

Based on research evidence:

• Severe deficiency: < 10 ng/mL - strongly associated with RLS, particularly persistent symptoms 5
• Moderate deficiency: 10-20 ng/mL - associated with RLS in multiple studies 3, 5
• Target for repletion: Aim for > 20 ng/mL, though optimal levels for RLS remain undefined

Supplementation Strategy

If vitamin D deficiency is identified:

• Initiate vitamin D supplementation (typical dosing: 1000-2000 IU daily for maintenance, higher for repletion based on severity)
• This is adjunctive to guideline-recommended therapies, not a replacement
• Reassess symptoms after 8-12 weeks of repletion
• Consider co-supplementation with iron if ferritin < 75 ng/mL (per AASM iron parameters)

Important Caveats

1. Guideline hierarchy: The AASM guideline does not support vitamin D as standard treatment, so it should not replace evidence-based therapies (gabapentinoids, iron, opioids for refractory cases) 1

2. Association vs. causation: While research shows associations, the causal relationship remains incompletely established 7

3. Cost-effectiveness: Empiric vitamin D supplementation is inexpensive and safe, making it reasonable to trial in deficient patients even without definitive RCT evidence 2

4. Measurement variability: Different assay methods yield different results; liquid chromatography-tandem mass spectrometry is most accurate 5

5. No evidence for PLMs specifically: Research focuses on RLS; evidence for isolated PLMD is absent

Practical Algorithm

For RLS patients:

1. Initiate guideline-recommended therapy (gabapentinoids or IV iron if appropriate iron parameters) 1
2. Check 25(OH)D level and ferritin/TSAT
3. If vitamin D < 20 ng/mL: supplement and recheck in 8-12 weeks
4. If inadequate response despite vitamin D repletion: escalate per AASM guidelines
5. If vitamin D > 20 ng/mL and symptoms persist: do not supplement vitamin D; focus on other guideline-recommended options

The evidence suggests vitamin D deficiency may contribute to RLS pathophysiology through interactions with dopamine, iron metabolism, and neurotransmitter systems 7, but checking and correcting deficiency should complement, not replace, guideline-directed therapy.